Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Radiology, Keijinkai Maruyama Clinic, Sapporo, Japan.
J Gastroenterol Hepatol. 2018 Dec;33(12):2048-2054. doi: 10.1111/jgh.14266. Epub 2018 May 17.
Previous cross-sectional studies showed that pancreatic fat was associated with metabolic syndrome. However, no longitudinal study has evaluated whether people with high pancreatic fat are likely to develop future metabolic syndrome. This study investigated the association between baseline pancreatic fat and metabolic syndrome incidence.
In 2008-2009, 320 participants without metabolic syndrome underwent health checks, which included unenhanced computed tomography, and were followed up annually for 4-5 years. Baseline pancreatic fat amounts were evaluated using a histologically validated method that measured differences between pancreas and spleen attenuations on computed tomography. The participants were divided into low (reference), intermediate, and high pancreatic fat groups based on pancreas and spleen attenuation tertiles. Metabolic syndrome incidence was evaluated annually over a median follow-up period of 4.99 (interquartile range, 4.88-5.05) years, in accordance with the 2009 harmonized criteria. Risk ratios (RRs) for the association between baseline pancreatic fat amounts and metabolic syndrome incidence were estimated using Poisson regression models adjusted for age, sex, body mass index, liver fat, pre-metabolic syndrome, cigarette use, alcohol use, and physical activity.
Metabolic syndrome incidence was 30.6% (98/320). Pancreatic fat was associated with an increased incidence of metabolic syndrome, based on a univariate analysis (RRs [95% confidence interval], 3.14 [1.74-5.67] and 3.96 [2.23-7.03] in the intermediate and high pancreatic fat groups, respectively). The association remained statistically significant in the multivariate analysis (RR [95% confidence interval], 2.04 [1.14-3.64] and 2.30 [1.28-4.14] for the same groups, respectively).
Pancreatic fat predicts the future risk of metabolic syndrome.
先前的横断面研究表明,胰腺脂肪与代谢综合征有关。然而,尚无纵向研究评估胰腺脂肪含量高的人群是否更易发生未来的代谢综合征。本研究旨在探讨基线胰腺脂肪与代谢综合征发生之间的关系。
2008-2009 年,320 名无代谢综合征的参与者接受了健康检查,包括未增强 CT,并在接下来的 4-5 年内每年进行随访。使用一种经组织学验证的方法评估基线胰腺脂肪量,该方法通过比较 CT 上胰腺和脾脏的衰减差异来测量。根据胰腺和脾脏衰减三分位数,将参与者分为低(参考)、中、高胰腺脂肪组。根据 2009 年的协调标准,在中位随访时间为 4.99 年(四分位距 4.88-5.05)的时间内,每年评估代谢综合征的发生情况。使用 Poisson 回归模型调整年龄、性别、体重指数、肝脂肪、前代谢综合征、吸烟、饮酒和体力活动等因素后,估计基线胰腺脂肪量与代谢综合征发生之间的风险比(RR)。
代谢综合征的发生率为 30.6%(98/320)。单因素分析显示胰腺脂肪与代谢综合征的发生率增加有关(RR [95%置信区间],中间组和高组分别为 3.14 [1.74-5.67] 和 3.96 [2.23-7.03])。多因素分析结果仍具有统计学意义(RR [95%置信区间],中间组和高组分别为 2.04 [1.14-3.64] 和 2.30 [1.28-4.14])。
胰腺脂肪预测未来代谢综合征的风险。